Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI
NCT ID: NCT02741154
Last Updated: 2017-09-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
50 participants
INTERVENTIONAL
2016-08-12
2017-09-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antagonist Protocol in Poor Responders
NCT02195947
Effect of GH Administration in Poor Responders Undergoing Intracytoplasmic Sperm Injection (ICSI)
NCT05281341
Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS
NCT03996434
Intrauterine Injection of Human Chorionic Gonadotrophin and Pregnancy Rate in ICSI
NCT03445910
Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support
NCT05286554
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study group will receive same management plus letrozole 2.5mg daily start at the first day of menses for 5 days and continue with same protocol
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
aromataze group
patients will receive induction with HMG plus aromataze inhibitor plus GnRh antagonist plus HCG injection
induction with aromataze inhibitor
letrozole 2.5mg once daily start in the first day of menses for 5days
HMG
HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
GnRh a
antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection
HCG
10.000 IU HCG injection when at least three follicles reach 17mm in diameter
classic group
same protocol for induction without aromataze inhibitor
HMG
HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
GnRh a
antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection
HCG
10.000 IU HCG injection when at least three follicles reach 17mm in diameter
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
induction with aromataze inhibitor
letrozole 2.5mg once daily start in the first day of menses for 5days
HMG
HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
GnRh a
antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection
HCG
10.000 IU HCG injection when at least three follicles reach 17mm in diameter
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ovarian factor
* Tubal factor
* Unexplained infertility
* poor responders
Exclusion Criteria
* Endometriosis
* Male and uterine factors
* Ovarian mass or cyst
18 Years
44 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Minia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Reham Elkhateeb
doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Minia University
Minya, Minya Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mitwally MF, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril. 2002 Apr;77(4):776-80. doi: 10.1016/s0015-0282(01)03280-0.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MUH20167
Identifier Type: REGISTRY
Identifier Source: secondary_id
MUH 20167
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.